The 2019 J.P. Morgan Healthcare Conference will be here soon. Prepare with our latest eBook. Download Now

Westicke Partners IPO Advisory
Strategic Investor Relations
Independent Capital Markets Advice

Mobile Navigation

Westwicke Blog

The Westwicke Blog is designed to deliver information and insights into the ever-changing world of investor relations and the capital markets, with a specific focus on the healthcare industry.

Will the Hong Kong Exchange Rival NASDAQ For Biotech IPOs?

Posted on September 12th, 2018. Posted by


In April 2018, the Hong Kong Exchange announced a change to its listing rules to allow (among other things) biotechnology companies with no revenue to list on the bourse. The move came as Hong Kong sought to establish itself as a financing hub for pre-revenue companies, in the face of fierce competition from the Chinese mainland and Singapore, exchanges from which had been aggressively wooing companies with fast-growing earnings.

Continue Reading

Dealing with Date Conflicts Around Earnings Calls and Investor Events

Posted on December 6th, 2017. Posted by

Dealing with Date Conflicts Around Earnings Calls and Investor Events

One of the perennial issues during earnings season is setting a date for your quarterly financial release that doesn’t clash with a dozen or so of your peers. By choosing a date that’s too crowded, investor and analyst participation may be low. The same problem can happen when choosing a date for an R&D day or investor day. So how do you go about choosing a date for your event that doesn’t clash with everyone else’s?

The answer is you don’t. Or rather, you shouldn’t waste your time thinking too much about it. First, I’ll talk a little about why you shouldn’t overthink the matter, then I’ll address what you can do to combat low live participation on your call or at your event.

Continue Reading

Investor Relations: The Evolution of a Compelling Biotech Deck

Posted on August 23rd, 2017. Posted by

Evolution of a Biotech Corporate Deck

The story of development-stage biotech companies is one of continuous fundraising. Not until approved products generate enough revenue to ensure a degree of self-sufficiency can you take a break from raising capital.

This process can take many years and many companies won’t make it. Either they’ll be acquired along the way or their product will fail one or more clinical trials.

Continue Reading

How to Deal With That One Difficult Research Analyst

Posted on April 5th, 2017. Posted by

In the film “Peter’s Friends,” Rita Rudner’s character, the star of a fictional sitcom, turns to her husband at the airport and laments, “You know what I hate about being a public figure? The public.”

I’m sure many executives running public companies have shared a similar sentiment from time to time.

The good news is that, alongside your trusted investor relations counsel, there is a group of professionals who can act as a barrier between you and the mass of institutional and private investors, namely sell-side research analysts.

Continue Reading

How to Engage with Sell-Side Analysts: Tips from the Source

Posted on November 2nd, 2016. Posted by

How to Engage with Sell-Side Analysts: Tips from the Source

As part of our Investor Relations Luncheon Series, we recently hosted a select group of biotechnology executives for a discussion with David Nierengarten and Heather Behanna, biotech analysts with Wedbush. The theme of the lunch was “How Best to Engage with Research Analysts.”

Continue Reading


Click here to download our latest eBook, J.P. Morgan Healthcare Conference: Your Keys to Success, for insight into how to prepare for the 2019 event.


Our Locations